NASDAQ · Financial Statements

Arcadia Biosciences, Inc. (RKDA) Revenue, Earnings & Financial Statements

$0.19 NASDAQ: RKDA Market Cap $293526

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Arcadia Biosciences, Inc. most recently reported annual revenue of $5.0M, a net loss of $2.0M. Revenue declined at an average annual rate of 9.0% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Arcadia Biosciences, Inc.: Revenue rose from $3.0M in 2016 to $5.0M in 2025, a change of +66.7% over 9 years; net profit was positive in 0 of 10 reported years; operating margin moved from -584.1% to -205.7%, a shift of +378.3 percentage points; the most recent year shows a net loss of $2.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$3.0M$4.0M$1.0M$1.0M$8.0M$7.0M$7.0M$4.0M$5.0M$5.0M
Operating Expenses$22.0M$18.0M$18.0M$21.0M$21.0M$42.0M$21.0M$11.0M$9.0M$15.0M
Operating Profit−$19.0M−$14.0M−$17.0M−$19.0M−$13.0M−$36.0M−$14.0M−$6.0M−$4.0M−$10.0M
Operating Margin-584.1%-355.6%-1152.3%-1657.9%-159.1%-524.0%-188.8%-137.0%-72.3%-205.7%
Other Income−$1.0M−$1.0M$3.0M−$9.0M$7.0M$19.0M$3.0M$1.0M−$1.0M$8.0M
Interest$1.0M$1.0M$3.0M$0$0$0$0$0$0$0
Depreciation$0$0$0$0$1.0M$1.0M$0$0$1.0M$0
Profit Before Tax−$20.0M−$16.0M−$13.0M−$29.0M−$6.0M−$16.0M−$11.0M−$5.0M−$4.0M−$2.0M
Tax rate (%)-0.1%-0.2%-0.1%-0.0%2.0%-0.0%-0.1%-0.1%-0.2%-0.3%
Net Profit−$20.0M−$16.0M−$13.0M−$29.0M−$5.0M−$15.0M−$15.0M−$14.0M−$7.0M−$2.0M
EPS−$353.85−$291.38−$143.16−$181.50−$24.20−$30.33−$26.05−$11.30−$5.16−$1.71

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$1.0M$1.0M$1.0M$2.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$2.0M
Operating Expenses$5.0M$3.0M−$1.0M$3.0M$3.0M$2.0M$7.0M$3.0M$2.0M$2.0M$2.0M$2.0M
Operating Profit−$3.0M−$2.0M$2.0M−$2.0M−$2.0M−$1.0M−$6.0M−$1.0M−$1.0M−$1.0M$0−$1.0M
Operating Margin-287.5%-160.9%151.6%-114.5%-187.4%-101.7%-411.7%-108.2%-152.6%-70.8%-34.4%-51.8%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$3.0M−$1.0M$2.0M−$1.0M−$4.0M$3.0M−$4.0M$1.0M−$1.0M−$4.0M−$6.0M$2.0M
Tax rate (%)-0.3%0.0%0.0%0.0%-0.2%0.0%0.0%0.0%-0.6%0.0%0.0%0.0%
Net Profit−$3.0M−$2.0M$1.0M−$2.0M−$4.0M$3.0M−$4.0M$1.0M−$1.0M−$4.0M−$6.0M$2.0M
EPS−$2.22−$1.78$0.78−$1.18−$2.98$1.90−$3.26$0.62−$0.98−$3.21−$4.58$0.29

Over the 10 years reported for Arcadia Biosciences, Inc., borrowings decreased from $25.0M in 2016 to $0 in 2025, cash stood at $0 in the latest year, shareholders' equity was $0, current assets covered current liabilities 3.00 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$57.0M$17.0M$24.0M$33.0M$47.0M$44.0M$29.0M$20.0M$14.0M$7.0M
Current Assets$52.0M$15.0M$23.0M$28.0M$32.0M$35.0M$25.0M$15.0M$9.0M$6.0M
Cash$2.0M$9.0M$12.0M$8.0M$14.0M$29.0M$21.0M$7.0M$4.0M$0
Inventory$0$0$0$2.0M$4.0M$4.0M$2.0M$2.0M$1.0M$1.0M
Receivables$1.0M$1.0M$0$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$0
Fixed Assets$1.0M$0$0$4.0M$9.0M$5.0M$3.0M$1.0M$0$0
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$51.0M$4.0M$10.0M$17.0M$12.0M$0$0$5.0M$0$4.0M
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$34.0M$9.0M$11.0M$24.0M$19.0M$13.0M$8.0M$7.0M$7.0M$2.0M
Current Liabilities$3.0M$4.0M$3.0M$6.0M$6.0M$5.0M$4.0M$4.0M$3.0M$2.0M
Borrowings$25.0M$0$0$2.0M$9.0M$3.0M$2.0M$1.0M$0$0
Other Liabilities$9.0M$9.0M$11.0M$22.0M$9.0M$9.0M$6.0M$6.0M$7.0M$2.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$22.0M$8.0M$13.0M$8.0M$28.0M$31.0M$21.0M$13.0M$6.0M$4.0M

For Arcadia Biosciences, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $5.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow−$17.0M−$14.0M−$14.0M−$17.0M−$30.0M−$26.0M−$14.0M−$15.0M−$10.0M−$5.0M
Investing Cash Flow−$11.0M$47.0M−$6.0M−$10.0M$15.0M$16.0M$1.0M−$4.0M$7.0M$1.0M
Financing Cash Flow$0−$1.0M$12.0M$14.0M$9.0M−$1.0M$0$0$0$0
Net Cash Flow−$22.0M$7.0M$3.0M−$4.0M$8.0M$13.0M−$8.0M−$14.0M−$2.0M−$4.0M
Free Cash Flow−$17.0M−$14.0M−$14.0M−$19.0M−$33.0M−$27.0M−$14.0M−$15.0M−$10.0M−$5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.25
FCF Yield-1054.80%
Quick Ratio2.82
Interest Coverage—
Return 1Y-94.35%
Return 3Y-93.21%
Return 5Y-99.70%

Arcadia Biosciences, Inc. (RKDA) financials — frequently asked questions

What is Arcadia Biosciences, Inc.'s annual revenue?

Arcadia Biosciences, Inc. (RKDA) reported annual revenue of $5.0M in its most recent fiscal year.

What is Arcadia Biosciences, Inc.'s net profit?

Arcadia Biosciences, Inc. (RKDA) reported a net loss of $2.0M in its most recent fiscal year.

What is RKDA EV/EBITDA?

Arcadia Biosciences, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 0.25.

Revenue and earnings of other Agricultural Inputs stocks

VYLR stockNTR revenue $26.9BCF revenue $7.1BMOS revenue $12.1BCTVA revenue $17.4BICL revenue $7.2BSMG revenue $3.3BFMC revenue $3.5BIPI revenue $298.0MAVD revenue $515.0MAll Agricultural Inputs stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Basic Materials StocksLow P/E Basic Materials StocksHigh Net Margin Basic Materials StocksDividend Basic Materials StocksLow Debt Basic Materials StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
RKDA Overview RKDA Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.